The national dialogue on value in health care is bringing to the forefront the limitations of current value assessment methods and gaps in real world data to inform decision-making. IVI seeks to engage a wider group of stakeholders to inform priorities in methods research and to invest resources and expertise in improving value assessment. Toward [...]
IVI presented two posters at AMCP Nexus 2019, the healthcare conference at the intersection of value and care. In the poster “Understanding Value Through the Patient’s Eyes: Perspectives from Patients with Genetic Mutations in Non-Small Cell Lung Cancer Treatment” researchers show how they examine the perspectives and experiences of patients diagnosed with mNSCLC, and the [...]
In a new Value Blueprints research brief, IVI explores the concept of “structural uncertainty,” an important source of uncertainty that is not generally measured or addressed in cost-effectiveness models. In this research brief, we use the IVI-RA model to demonstrate how different structural assumptions lead to varying cost-effectiveness estimates. As our findings make clear, it [...]
In a new Value Blueprints research brief, IVI explores the novel concept of “Insurance Value.” New medical technologies not only benefit patients, but also healthy people at risk of future illness. The insurance value arising from the decreased physical risk from illness is a potentially important dimension to consider in value assessment, especially when decisions [...]
IVI launches a new research brief series to present research findings and method insights from the OSVP. Let’s sparks a conversation into next-gen value assessment. Read the full press release here.
IVI's Lead Scientific Advisor and Lead Economist for the Open-Source Value Platform (OSVP), Jeroen Jansen and Devin Incerti, respectively, collaborate with Jeffery Curtis in a recent article published in the Journal of Managed Care and Specialty Pharmacy about how IVI’s open-source approach to value assessment provides a way to adapt formal assessments of value—long the [...]
IVI research into six pre-2016 ICER studies reveals an overestimation of “unmanaged” drug use and drug cost trends. The peer-reviewed research, published in Value in Health, illustrates the difficulty in predicting budget impact and the consequences of not accounting for uncertainty in value assessment. Read the full article here.
Los Angeles, CA – November 15, 2018 – The Innovation and Value Initiative (IVI) – a nonprofit dedicated to advancing the science and improving the practice of value assessment in healthcare – today released qualitative research evaluating what factors most impact the value of treatment to metastatic non-small cell lung cancer patients. According to the [...]
IVI has released the results to their non-small cell lung cancer patient qualitative research, which was used in the development of the structure of upcoming OSVP designed to evaluate lung cancer therapy sequences. According to the research, which was conducted in collaboration with LUNGevity, patients reported valuing treatments that would help increase overall or progression [...]
Priorities Emerged Which Will Shape Version 2.0 of IVI’s RA Model Los Angeles, CA – September 20, 2018 -- The Innovation and Value Initiative (IVI) today released public feedback and recommendations from its Technical Expert Panel (TEP), an objective third party comprised of five leaders in health economics, epidemiology, rheumatology, and patient communities, which the [...]
